Stockreport

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metas...

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival ("PFS") and overall survival ("OS") in an interim analysis of a Phase 3 t [Read more]